Science News

Cascade Amplifiers of Intracellular ROS based on Mitochondria-Targeted Core-Shell ZnO-TPP@D/H Nanorods for Breast Cancer Therapy.

A new interesting article has been published in ACS Appl Mater Interfaces. 2018 Oct 19. doi: 10.1021/acsami.8b12590. [Epub ahead of print] and titled:

Cascade Amplifiers of Intracellular ROS based on Mitochondria-Targeted Core-Shell ZnO-TPP@D/H Nanorods for Breast Cancer Therapy.

Authors of this article are:

Liang X, Xu SM, Zhang J, Li J, Shen Q.

A summary of the article is shown below:

Tumor cells are vulnerable to reactive oxygen species (ROS). However, it is still a challenge to induce ROS efficiently in tumor cells. In this study, cascade amplifiers of intracellular ROS based on charge-reversible mitochondria-targeted ZnO-TPP@D/H nanorods were firstly developed for breast cancer therapy. The core-shell ZnO-TPP@D/H nanorod with particle size of 179.60 ± 5.67 nm was composed of a core of ZnO nanorod, an inner shell of triphenyl phosphonium (TPP), and an outer shell of heparin. DOX was loaded on ZnO-TPP@D/H nanorods with high drug loading efficiency of 22.00 ± 0.18%. The zeta potential of ZnO-TPP@D/H nanorods varied from 24.00 ± 0.83 mV to -34.06 ± 0.87 mV after heparin coating, protecting ZnO-TPP@D/H nanorods from nonspecific adsorption in circulation. Mitochondrial targeting was achieved after the degradation of heparin. Cellular uptake assays showed that ZnO-TPP@D/H nanorods could accumulate in mitochondria. ROS generation assays showed that ZnO-TPP@D/H nanorods could triple the intracellular ROS in 4T1 cells (highly metastatic breast cancer cells) than free DOX. Western blot demonstrated that ZnO-TPP@D/H nanorods dramatically induced cell apoptosis in 4T1 cells. In vivo experiments suggested the anti-tumor potential of ZnO-TPP@D/H nanorods.

Check out the article’s website on Pubmed for more information:



This article is a good source of information and a good way to become familiar with topics such as:

n/a

.

Categories: Science News